Twist Bioscience FY26 Q3 adjusted EBITDA loss narrows to $(11.3) million; revenue rises 23% YoY to $118.4 million - TWST News | RalliesTwist Bioscience FY26 Q3 adjusted EBITDA loss narrows to $(11.3) million; revenue rises 23% YoY to $118.4 million
T
TWST• Segment performance
- DNA synthesis and protein solutions revenue climbed 39% year over year to $56.6 million, with about 369,000 genes shipped.
- NGS applications revenue increased 12% year over year to $61.8 million, with growth led by diagnostic customers.
Quarterly revenue and profitability
- Twist Bioscience posted fiscal third-quarter revenue of $118.4 million, up 23% year over year, beating guidance of $114 million-$115 million.
- Gross margin rose to 52.8%, up about 120 basis points sequentially from fiscal second quarter.
- Adjusted EBITDA loss narrowed to $11.3 million as the company said it is on track for breakeven in fiscal fourth quarter.
•
